AstraZeneca Hits Another Drug Setback | Business and Finance News

AstraZeneca hits another roadblock as it halts its Volrustomig lung cancer trial, finding no survival benefit over standard chemo — adding to a string of recent setbacks across its pipeline. Yet, the company flashes a few bright spots: two late-stage lung cancer trials delivered positive results, and Enhertu and Tagrisso showed strong efficacy in specific cancers. While shares edged up slightly, they remain down for the year — and investors are watching closely as AstraZeneca pivots Volrustomig toward cervical and mesothelioma trials, hoping to turn disappointment into breakthrough. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/222359ddf2391523